Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 13, 2026
Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG)Ozden Demir, Bulent Cetin, Ali Alkan, et al.
Eclinicalmedicine|May 25, 2026
Psychometric properties and clinical utility of the EORTC QLQ-BM22 in patients with bone metastases: a systematic reviewNicole Wisener, Britney Zhang, Henry C Y Wong, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|November 18, 2018
Perspective of Turkish Medicine Students on Cancer, Cancer Treatments, Palliative Care, and Oncologists (ARES Study): a Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)Esin Oktay, Mustafa Levent, Hakan Gelincik, et al.
Scientific Reports|November 30, 2024
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group studySerhat Sekmek, Sema Nur Ozsan Çelebi, Dogan Bayram, et al.
International Journal of Clinical Oncology|May 23, 2021
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with AtezolizumabDeniz Tural, Ömer Fatih Ölmez, Ahmet Taner Sümbül, et al.
Journal of Chemotherapy (Florence, Italy)|December 19, 2025
The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre studyBilgeşah Kılıçtaş, Murat Araz, Ahmet Oruç, et al.
JAMA Network Open|February 3, 2026
Development of a Health-Related Quality of Life Tool for Adolescents and Young Adults With CancerSamantha Claire Sodergren, Olga Husson, Silvie Janssen, et al.
European Urology Focus|October 3, 2020
Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life ExperiencesDeniz Tural, Ömer Fatih Ölmez, Ahmet Taner Sümbül, et al.
Pageof 10